Biora Therapeutics, Inc. (BIOR) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 15, 2022 4:06 PM EDTSuccessfully completed PM-602 human study for its targeted therapeutics platform demonstrating
promising device performance in active ulcerative colitis patients
Successfully completed PM-611 human study for its targeted therapeutics platform in healthy volunteers
showing promising performance regardless of feeding schedule
Confirmed planned phase 1 IND filing in Q1 based on FDA feedback on PGN-600 program in ulcerative
colitis
Strengthened patent position for both targeted and systemic therapeutics platforms
Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM... More
